Estetrol proven to have an estrogen antagonistic effect on breast tumour tissue

Pantarhei Bioscience study findings demonstrate the disappearance of breast tumours during treatment with the human fetal estrogen Estetrol

08-Jun-2012 - Netherlands

Pantarhei Bioscience (PRB  announced the publication of study results of the human fetal estrogen Estetrol (E4) in prevention and suppression of tumor growth in an in vivo mammary tumour model. The findings have been published in the Journal of Hormone Molecular Biology and Clinical Investigation (2012; 9(1): 95-103).

Pantarhei Bioscience is developing E4 for several Women’s Health applications amongst other hormone replacement therapy (HRT), oral contraception, osteoporosis, menstrual migraine and estrogen hormone sensitive cancers.

“Our results in the DMBA rat model for mammary tumour growth show that E4 prevents tumor initiation by DMBA and inhibits the growth of existing DMBA-induced tumors” concluded Monique Visser, PhD., principal scientist of the project and Program Director Estetrol at PRB. “The rat DMBA model is a mammary tumour model and the preferred tool to assess the potential in vivo prophylactic and therapeutic effects of new drugs in breast cancer.”

She added : “One particularly striking finding  was the fact that  E4 was found to have  an estrogen antagonistic effect on breast tumour tissue, especially surprising since other estrogenic hormones used in HRT and in contraception, such as Estradiol (E2) and Ethinylestradiol (EE), are known to have a stimulatory effect on breast cancer growth”.

Other news from the department research and development

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

Last viewed contents

Acacia Pharma initiates Phase IIA study with APD209 in cancer cachexia patients

MorphoSys und Astellas beginnen Antikörperpartnerschaft - Dritte therapeutische Allianz für MorphoSys in Japan

Addex Parkinson's Product Progressing in Early Clinical Trials

ArGEN-X initiates Phase Ib study of ARGX-110 in cancer

Prometic Finalizes Major Technology Licencing Agreement in Tunisia

Doug Berthiaume to Retire as Chairman of the Board of Waters Corporation - Chris O'Connell Elected as New Chairman

Horizon Discovery and Fox Chase Cancer Center announce collaboration to apply rAAV gene targeting in mouse embryonic stem cells and research into EGFR-therapy resistance. - Collaboration will establish a new Center Of Excellence in Mammalian Gene Editing

Hybrigenics receives first patent grant on chemical inhibitors of Ubiquitin-Specific Proteases

Aastrom Biosciences and Zellera AG Announce the Initiation of a Clinical Trial for Bone Grafting in Spain - Aastrom's Proprietary TRCs to be Utilized in Second European Clinical Study to Treat Major Bone Fractures

Movetis Announces Start of a Phase IIa trial for M0002 in Ascites

Addex Achieves Second Milestone in Parkinson's Disease Collaboration with Merck & Co., Inc. - Data Confirm Non-Dopaminergic Approach to Treating Parkinson's Disease

BioInvent extends antibody collaboration with Japanese pharmaceutical partner - Lead candidate for inflammation to progress into preclinical development